Literature DB >> 19499513

Maternal serum angiopoietin-2 at 11 to 13 weeks of gestation in hypertensive disorders of pregnancy.

Ranjit Akolekar1, Davide Casagrandi, Evdoxia Skyfta, Abubaker Abdalla Ahmed, Kypros H Nicolaides.   

Abstract

OBJECTIVE: In women with preeclampsia (PE), the serum concentration of the growth factor angiopoietin-2 (Ang-2) is significantly lower than in unaffected controls. The objective of this study is to determine if the decrease in serum Ang-2 is evident from the first trimester of pregnancy before the clinical onset of PE.
METHODS: Serum Ang-2 and uterine artery pulsatility index (PI) were measured at 11 to 13 weeks in 126 pregnancies that subsequently developed PE, 88 cases that developed gestational hypertension (GH) and 214 unaffected controls.
RESULTS: Maternal serum Ang-2 in the PE group [0.96 multiple of the median (MoM)] and in GH (1.12 MoM) was not significantly different from the unaffected group (1.07 MoM). Uterine artery PI was significantly higher in the PE group (1.32 MoM) but not in GH (1.11 MoM) compared to the unaffected group (1.05 MoM).
CONCLUSION: In pregnancies that develop PE there is Doppler evidence of impaired placentation from the first trimester of pregnancy. However, the impaired placentation is not reflected in altered maternal serum levels of Ang-2.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19499513     DOI: 10.1002/pd.2307

Source DB:  PubMed          Journal:  Prenat Diagn        ISSN: 0197-3851            Impact factor:   3.050


  2 in total

1.  Role of the angiopoietin/Tie system in pregnancy (Review).

Authors:  D Kappou; S Sifakis; A Konstantinidou; N Papantoniou; D A Spandidos
Journal:  Exp Ther Med       Date:  2015-02-09       Impact factor: 2.447

2.  Serum angiopoietin-2 and β-hCG as predictors of prolonged uterine bleeding after medical abortion in the first trimester.

Authors:  Maofeng Wang; Junqing Chen; Jun Ying; Jiong Yu; Bifei Huang; Zhaoxiang Ren; Xianyu Wang; Qiaoqiao Guo; Yunlai Wang; Liuyi Qiu; Hongsheng Yu; Rugen Wan
Journal:  PLoS One       Date:  2013-05-16       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.